Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Evolving Clostridium difficile Germs Spreading in Hospitals

By HospiMedica International staff writers
Posted on 19 Aug 2019
A new study reveals that Clostridium difficile, a bacterium that causes debilitating diarrhea, is evolving into two separate species, with one group highly adapted to spread in hospitals.

Researchers at the Wellcome Sanger Institute (Hinxton, United Kingdom), the London School of Hygiene & Tropical Medicine (LSHTM; United Kingdom), and other institutions undertook a large-scale genomic analysis of 906 strains of C. More...
difficile isolated from humans, animals (such as dogs, pigs and horses), and the environment. By sequencing the DNA of each strain, and comparing and analyzing all the genomes, the researchers discovered that classical C. difficile is currently evolving into another, separate species.

The emerging species, C. difficile clade A, made up approximately 70% of the samples from hospital patients. Clade A had changes in genes that metabolize simple sugars, as well as in the genes involved in forming spores, giving it much greater resistance to hospital disinfectants. Further analysis revealed that while Clade A first appeared about 76,000 years ago, the number of different strains started to increase at the end of the 16th Century, before the founding of modern hospitals. This group has since thrived in hospital settings, with many strains that keep adapting and evolving. The study was published on August 12, 2019, in Nature Genetics.

“Our study provides genome and laboratory based evidence that human lifestyles can drive bacteria to form new species so they can spread more effectively,” said senior Trevor Lawley, PhD, of the Wellcome Sanger Institute. “We show that strains of C. difficile bacteria have continued to evolve in response to modern diets and healthcare systems, and reveal that focusing on diet and looking for new disinfectants could help in the fight against this bacterium.”

“Our large-scale genetic analysis allowed us to discover that C. difficile is currently forming a new species, with one group specialized to spread in hospital environments,” said lead author Nitin Kumar, PhD, of the Wellcome Sanger Institute. “This emerging species has existed for thousands of years, but this is the first time anyone has studied C. difficile genomes in this way to identify it. This particular bacteria was primed to take advantage of modern healthcare practices and human diets, before hospitals even existed.”

C. difficile exists in the environment as a dormant spore. To colonize the gut, the spores need to germinate and turn in active, toxin-producing bacteria. Antibiotics that alter the gastrointestinal microbiota facilitate this germination, allowing C. difficile infection, a significant public health problem.

Related Links:
Wellcome Sanger Institute
London School of Hygiene & Tropical Medicine


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammography System (Analog)
MAM VENUS
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.